Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail Pharmaceuticals Inc.

Division of Bausch Health Companies Inc./Biovail Corp.
www.biovail.com

Latest From Biovail Pharmaceuticals Inc.

Deal Watch: AbbVie Bets On Turnstone’s Cancer Immunotherapy Technology

AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.

Deals Business Strategies

Teva's Huntington's Rejection May Be Neurocrine's Good Fortune

Teva Pharmaceutical Industries Ltd.'s bad luck in getting its experimental Huntington's disease drug deutetrabenazine (SD-809) across the FDA's finish line may be Neurocrine Bioscience's good fortune for its investigational agent valbenazine in another indication – tardive dyskinesia, a condition for which both companies are expected to file applications for their respective products in the US.

Companies Approvals

Valeant Buyout Brings Marketing Clout To Sprout And Addyi

Canada’s M&A specialist agrees to pay $1bn for the female sexual desire drug just two days after its FDA approval, taking the North Carolina firm in-house as a subsidiary focused on global registration of Addyi.

BioPharmaceutical United States

Deals of the Week: Options Abound As Forest Keeps Its Eyes On A Prize-Winner

Reflecting a long trend, three of this past week’s deals include option arrangements, including one with a new twist. Also, a rare disease partnership between Shire and Atlas Venture finally leads to a deal and Takeda continues building its vaccines business.

BioPharmaceutical Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register